KR20120132506A - 인플루엔자 바이러스 질환의 예방 및 치료에 사용되는 백신 - Google Patents
인플루엔자 바이러스 질환의 예방 및 치료에 사용되는 백신 Download PDFInfo
- Publication number
- KR20120132506A KR20120132506A KR1020127024205A KR20127024205A KR20120132506A KR 20120132506 A KR20120132506 A KR 20120132506A KR 1020127024205 A KR1020127024205 A KR 1020127024205A KR 20127024205 A KR20127024205 A KR 20127024205A KR 20120132506 A KR20120132506 A KR 20120132506A
- Authority
- KR
- South Korea
- Prior art keywords
- polypeptide
- amino acid
- core polypeptide
- cold
- core
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract description 191
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 31
- 201000010099 disease Diseases 0.000 title claims description 30
- 229960005486 vaccine Drugs 0.000 title abstract description 15
- 238000011282 treatment Methods 0.000 title description 5
- 238000011321 prophylaxis Methods 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 1471
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 1463
- 229920001184 polypeptide Polymers 0.000 claims abstract description 1460
- 101710154606 Hemagglutinin Proteins 0.000 claims abstract description 144
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims abstract description 144
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims abstract description 144
- 101710176177 Protein A56 Proteins 0.000 claims abstract description 144
- 239000000185 hemagglutinin Substances 0.000 claims abstract description 138
- 238000000034 method Methods 0.000 claims abstract description 110
- 206010022000 influenza Diseases 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 150000001413 amino acids Chemical class 0.000 claims description 503
- 239000012634 fragment Substances 0.000 claims description 175
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 135
- 125000005647 linker group Chemical group 0.000 claims description 80
- 230000002209 hydrophobic effect Effects 0.000 claims description 70
- 210000004027 cell Anatomy 0.000 claims description 65
- 108020004707 nucleic acids Proteins 0.000 claims description 64
- 150000007523 nucleic acids Chemical class 0.000 claims description 64
- 102000039446 nucleic acids Human genes 0.000 claims description 64
- 241000700605 Viruses Species 0.000 claims description 51
- 108090000623 proteins and genes Proteins 0.000 claims description 48
- 102000004169 proteins and genes Human genes 0.000 claims description 41
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 37
- 230000002163 immunogen Effects 0.000 claims description 34
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 29
- 230000009385 viral infection Effects 0.000 claims description 29
- 229910052700 potassium Inorganic materials 0.000 claims description 17
- 230000027455 binding Effects 0.000 claims description 16
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 13
- 230000003053 immunization Effects 0.000 claims description 13
- 102000007999 Nuclear Proteins Human genes 0.000 claims description 12
- 108010089610 Nuclear Proteins Proteins 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 102000014914 Carrier Proteins Human genes 0.000 claims description 10
- 108010078791 Carrier Proteins Proteins 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 9
- 241000712431 Influenza A virus Species 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 208000037797 influenza A Diseases 0.000 claims description 8
- 108010040721 Flagellin Proteins 0.000 claims description 7
- 241000607142 Salmonella Species 0.000 claims description 6
- 102000002689 Toll-like receptor Human genes 0.000 claims description 6
- 108020000411 Toll-like receptor Proteins 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 5
- 239000011159 matrix material Substances 0.000 claims description 5
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 230000003472 neutralizing effect Effects 0.000 claims description 4
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 2
- 241000713196 Influenza B virus Species 0.000 claims description 2
- 241000700618 Vaccinia virus Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 229920003023 plastic Polymers 0.000 claims 1
- 239000004033 plastic Substances 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 230000028993 immune response Effects 0.000 abstract description 46
- 235000001014 amino acid Nutrition 0.000 description 423
- 102100035824 Unconventional myosin-Ig Human genes 0.000 description 44
- 241000282472 Canis lupus familiaris Species 0.000 description 41
- 235000018102 proteins Nutrition 0.000 description 34
- 238000002560 therapeutic procedure Methods 0.000 description 29
- 230000000694 effects Effects 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 22
- 208000015181 infectious disease Diseases 0.000 description 21
- 239000013604 expression vector Substances 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 18
- 230000003612 virological effect Effects 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 238000002649 immunization Methods 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 230000029812 viral genome replication Effects 0.000 description 11
- 230000009467 reduction Effects 0.000 description 10
- 230000010076 replication Effects 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 6
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000012707 chemical precursor Substances 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 108010006232 Neuraminidase Proteins 0.000 description 5
- 102000005348 Neuraminidase Human genes 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- -1 norleucine Chemical class 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 230000001932 seasonal effect Effects 0.000 description 5
- 239000013638 trimer Substances 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 230000021736 acetylation Effects 0.000 description 4
- 238000006640 acetylation reaction Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 229940079920 digestives acid preparations Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 238000002864 sequence alignment Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000005829 trimerization reaction Methods 0.000 description 4
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 241000702620 H-1 parvovirus Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000001323 posttranslational effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- 238000003892 spreading Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 2
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 2
- 150000008575 L-amino acids Chemical group 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BVIAOQMSVZHOJM-UHFFFAOYSA-N N(6),N(6)-dimethyladenine Chemical compound CN(C)C1=NC=NC2=C1N=CN2 BVIAOQMSVZHOJM-UHFFFAOYSA-N 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 241000712464 Orthomyxoviridae Species 0.000 description 2
- 241000702437 Parvovirus H3 Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 206010064097 avian influenza Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000013357 binding ELISA Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- VYLDEYYOISNGST-UHFFFAOYSA-N bissulfosuccinimidyl suberate Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VYLDEYYOISNGST-UHFFFAOYSA-N 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 108700010900 influenza virus proteins Proteins 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 230000004768 organ dysfunction Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 230000007030 peptide scission Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
- HJBUBXIDMQBSQW-UHFFFAOYSA-N 4-(4-diazoniophenyl)benzenediazonium Chemical compound C1=CC([N+]#N)=CC=C1C1=CC=C([N+]#N)C=C1 HJBUBXIDMQBSQW-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 241000608297 Getah virus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000610797 Haloviruses Species 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000428199 Mustelinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282373 Panthera pardus Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000008234 Toll-like receptor 5 Human genes 0.000 description 1
- 108010060812 Toll-like receptor 5 Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 244000309457 enveloped RNA virus Species 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 208000037799 influenza C Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013520 translational research Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 230000006656 viral protein synthesis Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30589810P | 2010-02-18 | 2010-02-18 | |
| US61/305,898 | 2010-02-18 | ||
| US12/788,103 | 2010-05-26 | ||
| US12/788,103 US8673314B2 (en) | 2009-05-26 | 2010-05-26 | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
| US35416010P | 2010-06-11 | 2010-06-11 | |
| US61/354,160 | 2010-06-11 | ||
| US38508310P | 2010-09-21 | 2010-09-21 | |
| US61/385,083 | 2010-09-21 | ||
| PCT/US2011/025467 WO2011103453A2 (en) | 2010-02-18 | 2011-02-18 | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20120132506A true KR20120132506A (ko) | 2012-12-05 |
Family
ID=44483593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127024205A Ceased KR20120132506A (ko) | 2010-02-18 | 2011-02-18 | 인플루엔자 바이러스 질환의 예방 및 치료에 사용되는 백신 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9701723B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2536425B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2013520172A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20120132506A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102939096B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011217903B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012020839A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2790380A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX342716B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011103453A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2787099A1 (en) | 2009-03-30 | 2010-10-14 | Anice C. Lowen | Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof |
| AU2010254136B2 (en) | 2009-05-26 | 2016-09-29 | Mount Sinai School Of Medicine | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
| US9701723B2 (en) | 2010-02-18 | 2017-07-11 | Icahn School Of Medicine At Mount Sinai | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
| EP3248615A1 (en) | 2010-03-30 | 2017-11-29 | Mount Sinai School of Medicine of New York University | Influenza virus vaccines and uses thereof |
| CN108164602A (zh) | 2011-09-20 | 2018-06-15 | 西奈山医学院 | 流感病毒疫苗及其应用 |
| CN108641002A (zh) | 2012-12-18 | 2018-10-12 | 西奈山伊坎医学院 | 流感病毒疫苗及其用途 |
| US9908930B2 (en) | 2013-03-14 | 2018-03-06 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| CA2974699A1 (en) | 2015-01-23 | 2016-07-28 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| KR101768600B1 (ko) * | 2015-05-18 | 2017-08-17 | 한국생명공학연구원 | 범용성 개 인플루엔자 바이러스 백신 조성물 |
| JP6868763B2 (ja) * | 2016-04-01 | 2021-05-12 | パナソニックＩｐマネジメント株式会社 | インフルエンザウィルスに結合する抗体 |
| MX2018015755A (es) | 2016-06-15 | 2019-08-29 | Icahn School Med Mount Sinai | Proteinas de hemaglutinina de virus de influenza y usos de las mismas. |
| US10478488B2 (en) | 2017-10-03 | 2019-11-19 | Southwest Research Institute | Liposomal flu vaccine formulation |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EP3606555A4 (en) | 2017-04-07 | 2021-08-04 | Icahn School of Medicine at Mount Sinai | INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF |
| ES2991988T3 (es) | 2017-10-30 | 2024-12-05 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica |
| RU2757013C2 (ru) * | 2017-12-19 | 2021-10-08 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации | Рекомбинантная противогриппозная вакцина с широким спектром защиты и способ ее получения |
| CN108287235B (zh) * | 2018-02-07 | 2021-03-09 | 常州天地人和生物科技有限公司 | 一种高效、稳定的磁性免疫微球的制备和应用 |
| CN108329379B (zh) * | 2018-04-08 | 2022-01-28 | 诺华生物科技（武汉）有限责任公司 | H7亚型流感病毒h7n9的普通型/嵌合型病毒样颗粒及制备方法、应用和疫苗 |
| CN108840911B (zh) * | 2018-06-09 | 2021-03-30 | 西北农林科技大学 | 新城疫病毒基质蛋白的抗原表位、抗体、鉴定方法和应用 |
| US12364746B2 (en) | 2018-06-21 | 2025-07-22 | Icahn School Of Medicine At Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
| WO2020022272A1 (ja) | 2018-07-23 | 2020-01-30 | 公益財団法人ヒューマンサイエンス振興財団 | インフルエンザワクチンを含む組成物 |
| CN109097341B (zh) * | 2018-08-28 | 2021-09-24 | 青岛农业大学 | 一种同时表达ha和hef的复制缺陷型重组流感病毒 |
| CN111363017B (zh) * | 2018-12-25 | 2022-03-15 | 中国科学院微生物研究所 | A型流感病毒核蛋白s69位突变序列及其突变体与应用 |
| EP3936147A4 (en) | 2019-03-04 | 2022-09-28 | JAPAN as represented by DIRECTOR GENERAL of National Institute of Infectious Diseases | METHOD FOR PREPARING A SPLIT VACCINE AGAINST INFLUENZA HEMAGGLUTININ (HA) |
| TWI857017B (zh) * | 2019-03-04 | 2024-10-01 | 國立感染症研究所長代表之日本國 | 流感ha裂解疫苗之製造方法 |
| CN111134250A (zh) * | 2019-12-03 | 2020-05-12 | 海南大学 | 一种草地贪夜蛾幼虫食用人工饲料的配方和制作方法 |
| CN111298098B (zh) * | 2020-02-25 | 2021-10-29 | 中国科学院微生物研究所 | 卡泊芬净在制备抑制冠状病毒的产品中的应用 |
| EP4120863A4 (en) * | 2020-03-19 | 2024-04-24 | Renibus Therapeutics, Inc. | METHOD FOR TREATING CORONAVIRUS INFECTION |
| CN117229370B (zh) * | 2022-06-08 | 2024-11-01 | 中科南京生命健康高等研究院 | H5n6禽流感广谱性疫苗的开发及其应用 |
| WO2024097396A1 (en) * | 2022-11-05 | 2024-05-10 | Us Biologic, Inc. | Visco-elastic solid formulation for oral delivery of a biologically active agent |
| WO2025106608A2 (en) * | 2023-11-15 | 2025-05-22 | Red Queen Therapeutics, Inc. | Antiviral structurally stapled influenza peptides and uses thereof |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA836080B (en) * | 1982-08-23 | 1984-04-25 | Scripps Clinic Res | Broad spectrum influenza antisera |
| US5182192A (en) | 1987-03-27 | 1993-01-26 | The Wistar Institute | Monoclonal antibodies against glycolipid antigens, methods of producing these antibodies, and use therefor |
| US6001634A (en) | 1989-08-28 | 1999-12-14 | Palese; Peter | Recombinant negative strand RNA viruses |
| US5854037A (en) | 1989-08-28 | 1998-12-29 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand RNA virus expression systems and vaccines |
| US6887699B1 (en) | 1990-05-22 | 2005-05-03 | Medimmune Vaccines, Inc. | Recombinant negative strand RNA virus expression systems and vaccines |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| FR2664905B1 (fr) | 1990-07-18 | 1994-08-12 | Agronomique Inst Nat Rech | Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| EP0621339B1 (en) | 1992-09-17 | 2001-10-24 | Takara Shuzo Co. Ltd. | Immunogenic human influenza A virus haemagglutinin polypeptides |
| US5589174A (en) | 1992-09-17 | 1996-12-31 | Takara Shuzo Co., Ltd. | Anti-human influenza virus antibody |
| US6337070B1 (en) | 1993-04-29 | 2002-01-08 | Takara Shuzo Co., Ltd. | Polypeptides for use in generating anti-human influenza virus antibodies |
| JP3037554B2 (ja) | 1993-04-20 | 2000-04-24 | 寳酒造株式会社 | 免疫原性人工ポリペプチド |
| GB9221654D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant human anti-cytomegalovirus antibodies |
| WO1994016109A1 (en) * | 1993-01-15 | 1994-07-21 | Whitehead Institute For Biomedical Research | Membrane fusion events and means for altering same |
| WO1994017826A1 (en) | 1993-02-01 | 1994-08-18 | Smithkline Beecham Corporation | Vaccinal polypeptides |
| US5573916A (en) * | 1994-05-19 | 1996-11-12 | Coretech, Inc. | Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier |
| US5622701A (en) | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
| AU5632296A (en) | 1995-04-27 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| US6165476A (en) | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| MXPA01010921A (es) | 1999-04-29 | 2003-06-24 | Syngenta Ltd | Plantas resistentes a herbicidas. |
| DE60036952T2 (de) * | 1999-09-24 | 2008-08-07 | Glaxosmithkline Biologicals S.A. | Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung |
| US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
| CN100489107C (zh) * | 2000-04-28 | 2009-05-20 | 圣朱德儿童研究医院 | 用于产生感染性流感病毒的dna转染系统 |
| US6632620B1 (en) | 2000-06-22 | 2003-10-14 | Andrew N. Makarovskiy | Compositions for identification and isolation of stem cells |
| ES2806412T3 (es) | 2002-02-13 | 2021-02-17 | Wisconsin Alumni Res Found | Señal para el empaquetamiento de vectores del virus de la gripe |
| US20040091503A1 (en) | 2002-08-20 | 2004-05-13 | Genitrix, Llc | Lectin compositions and methods for modulating an immune response to an antigen |
| AU2004207838B2 (en) | 2003-01-29 | 2010-04-22 | The Research Foundation Of State University Of New York | Tolerance-induced targeted antibody production |
| JP4675317B2 (ja) * | 2003-01-30 | 2011-04-20 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | アジュバント化インフルエンザワクチン |
| JP4368594B2 (ja) * | 2003-02-24 | 2009-11-18 | 株式会社インシリコサイエンス | タンパク質構造予測装置、タンパク質構造予測方法、プログラム、および、記録媒体 |
| ATE473271T1 (de) | 2003-05-05 | 2010-07-15 | Thompson Boyce Plant Res | Vektoren und zellen zur herstellung von aus transgenen pflanzen gewonnenen immunprotektiven zusammensetzungen |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| DK2261376T3 (da) * | 2003-11-04 | 2013-10-07 | Univ Tulane | Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA vira med klasse I membranfusogene indhyldningsproteiner |
| EP2530147B1 (en) * | 2004-05-25 | 2014-09-10 | MedImmune, LLC | Influenza hemagglutinin and neuraminidase variants |
| CA2598884A1 (en) * | 2005-02-24 | 2006-10-05 | University Of Massachusetts | Influenza nucleic acids, polypeptides, and uses thereof |
| AU2006252406B2 (en) | 2005-06-01 | 2012-05-17 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
| JP4758148B2 (ja) | 2005-06-14 | 2011-08-24 | 泰三 宇田 | インフルエンザウイルスのヘマグルチニンに対する抗体酵素 |
| EP2368573A3 (en) * | 2005-11-04 | 2013-05-01 | Novartis Vaccines and Diagnostics S.r.l. | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| NZ595736A (en) | 2005-12-02 | 2013-05-31 | Sinai School Medicine | Chimeric viruses presenting non-native surface proteins and uses thereof |
| WO2007066334A1 (en) * | 2005-12-06 | 2007-06-14 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Improved influenza vaccine |
| US10183986B2 (en) * | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
| EP2476432B1 (en) | 2006-03-07 | 2015-08-19 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
| US8148085B2 (en) | 2006-05-15 | 2012-04-03 | Sea Lane Biotechnologies, Llc | Donor specific antibody libraries |
| EP2522678A1 (en) | 2006-05-15 | 2012-11-14 | Sea Lane Biotechnologies, LLC | Neutralizing antibodies to influenza viruses |
| CA2657849A1 (en) * | 2006-05-18 | 2008-05-08 | Pharmexa Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
| EP2035565A4 (en) | 2006-06-30 | 2010-07-21 | Novavax Inc | METHODS OF ENHANCING THE INCORPORATION OF PROTEINS IN VIRUS-LIKE PARTICLES (VLPs) |
| DK2048955T3 (da) | 2006-07-21 | 2013-09-02 | California Inst Of Techn | Målrettet gen-tilførsel til dendrit-cellevaccination |
| EA017203B1 (ru) | 2006-09-07 | 2012-10-30 | Круселл Холланд Б.В. | Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение |
| EA200970271A1 (ru) | 2006-09-11 | 2010-02-26 | Новартис Аг | Получение вакцин против вируса гриппа без использования куриных эмбрионов |
| ES2609818T3 (es) * | 2007-06-15 | 2017-04-24 | Xiamen University | Anticuerpos monoclonales que se unen a hemaglutinina del virus de la gripe aviar del subtipo H5 y usos de los mismos |
| EP2014279A1 (en) * | 2007-06-22 | 2009-01-14 | Pevion Biotech AG | Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof |
| CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
| WO2009025770A2 (en) | 2007-08-17 | 2009-02-26 | Wyeth | A heterologous prime-boost immunization regimen |
| US9421254B2 (en) * | 2007-09-24 | 2016-08-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunostimulatory combinations of TLR ligands and methods of use |
| FR2921387B1 (fr) | 2007-09-26 | 2012-04-20 | Sanofi Pasteur | Procede de production du virus de la grippe |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| KR20100120157A (ko) | 2007-11-27 | 2010-11-12 | 메디카고 인코포레이티드 | 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ) |
| CA2708221C (en) | 2007-12-06 | 2017-07-25 | Wayne A. Marasco | Antibodies against influenza virus and methods of use thereof |
| ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
| US20100040635A1 (en) | 2008-03-28 | 2010-02-18 | Sea Lane Biotechnologies | Neutralizing antibodies to influenza viruses |
| GB0905570D0 (en) | 2009-03-31 | 2009-05-13 | Novartis Ag | Combined vaccines |
| US8592557B2 (en) * | 2008-06-17 | 2013-11-26 | Apogenix Gmbh | Multimeric TNF receptor fusion proteins and nucleic acids encoding same |
| SI2300609T1 (sl) | 2008-06-25 | 2014-04-30 | Inserm Institut National De La Sante Et De La Recherche Medicale | Nove imunoadjuvantne spojine na osnovi flagelina in njihova uporaba |
| CN102089432A (zh) | 2008-07-08 | 2011-06-08 | 麦迪卡格公司 | 可溶性重组流感抗原 |
| CA2787099A1 (en) | 2009-03-30 | 2010-10-14 | Anice C. Lowen | Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof |
| US8470327B2 (en) | 2009-05-11 | 2013-06-25 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof |
| AU2010254136B2 (en) * | 2009-05-26 | 2016-09-29 | Mount Sinai School Of Medicine | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
| HRP20180706T1 (hr) | 2009-06-24 | 2018-06-01 | Medicago Inc. | Kimerna gripa nalik čestici koja sadrži hemaglutinin |
| US8828406B2 (en) * | 2009-07-30 | 2014-09-09 | Icahn School Of Medicine At Mount Sinai | Influenza viruses and uses thereof |
| JP5463107B2 (ja) | 2009-09-14 | 2014-04-09 | 独立行政法人国立国際医療研究センター | 新型インフルエンザを特異的に鑑別するモノクローナル抗体とそれを利用した免疫検出試薬 |
| JP2013060367A (ja) | 2010-01-15 | 2013-04-04 | Osaka Univ | 抗インフルエンザ抗体及びインフルエンザ検出用デバイス |
| US8298820B2 (en) * | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| US9701723B2 (en) | 2010-02-18 | 2017-07-11 | Icahn School Of Medicine At Mount Sinai | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
| KR101297784B1 (ko) | 2010-03-08 | 2013-08-20 | (주)셀트리온 | 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 인간 단일클론 항체 |
| EP3248615A1 (en) | 2010-03-30 | 2017-11-29 | Mount Sinai School of Medicine of New York University | Influenza virus vaccines and uses thereof |
| WO2012009790A1 (en) | 2010-07-22 | 2012-01-26 | Schrader John W | Cross-protective pathogen protection, methods and compositions thereof |
| CN108164602A (zh) | 2011-09-20 | 2018-06-15 | 西奈山医学院 | 流感病毒疫苗及其应用 |
| EP2785372B1 (en) | 2011-11-28 | 2019-06-19 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
| EP2931747B1 (en) | 2012-12-11 | 2020-06-10 | Vib Vzw | Anti-influenza antibody |
| CN108641002A (zh) | 2012-12-18 | 2018-10-12 | 西奈山伊坎医学院 | 流感病毒疫苗及其用途 |
-
2011
- 2011-02-18 US US13/579,845 patent/US9701723B2/en active Active
- 2011-02-18 AU AU2011217903A patent/AU2011217903B2/en not_active Ceased
- 2011-02-18 BR BR112012020839A patent/BR112012020839A2/pt not_active Application Discontinuation
- 2011-02-18 EP EP11745345.6A patent/EP2536425B1/en active Active
- 2011-02-18 MX MX2012009581A patent/MX342716B/es active IP Right Grant
- 2011-02-18 KR KR1020127024205A patent/KR20120132506A/ko not_active Ceased
- 2011-02-18 JP JP2012554060A patent/JP2013520172A/ja not_active Withdrawn
- 2011-02-18 WO PCT/US2011/025467 patent/WO2011103453A2/en not_active Ceased
- 2011-02-18 CA CA2790380A patent/CA2790380A1/en not_active Abandoned
- 2011-02-18 CN CN201180019658.1A patent/CN102939096B/zh not_active Expired - Fee Related
-
2016
- 2016-05-24 JP JP2016103689A patent/JP2016196472A/ja not_active Withdrawn
-
2018
- 2018-07-03 JP JP2018126633A patent/JP2018166515A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013520172A (ja) | 2013-06-06 |
| US20130209499A1 (en) | 2013-08-15 |
| AU2011217903A1 (en) | 2012-09-13 |
| JP2018166515A (ja) | 2018-11-01 |
| CN102939096A (zh) | 2013-02-20 |
| EP2536425A2 (en) | 2012-12-26 |
| MX342716B (es) | 2016-10-11 |
| US9701723B2 (en) | 2017-07-11 |
| AU2011217903B2 (en) | 2017-03-02 |
| BR112012020839A2 (pt) | 2017-11-21 |
| US20170114103A9 (en) | 2017-04-27 |
| CN102939096B (zh) | 2016-03-02 |
| JP2016196472A (ja) | 2016-11-24 |
| WO2011103453A3 (en) | 2011-12-29 |
| CA2790380A1 (en) | 2011-08-25 |
| EP2536425B1 (en) | 2019-06-19 |
| MX2012009581A (es) | 2013-01-29 |
| EP2536425A4 (en) | 2014-11-05 |
| WO2011103453A2 (en) | 2011-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9701723B2 (en) | Vaccines for use in the prophylaxis and treatment of influenza virus disease | |
| US10179806B2 (en) | Influenza virus vaccines and uses thereof | |
| US9849172B2 (en) | Influenza virus vaccines and uses thereof | |
| US10736956B2 (en) | Influenza virus vaccination regimens | |
| JP2020096604A (ja) | インフルエンザウイルスワクチン及びその使用 | |
| WO2019032463A1 (en) | IMMUNOGENIC COMPOSITIONS COMPRISING INFLUENZA VIRUS AND AS01 CHIMERIC POLYPEPTIDES OF HEMAGGLUTININ AND USES THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20120917 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20160218 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20171228 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20181127 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20171228 Comment text: Notification of reason for refusal Patent event code: PE06011S01I Patent event date: 20170531 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |